Ser1490

Site Information
AILNPPPsPAtERsH SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 456289

In vivo Characterization
Methods used to characterize site in vivo:	electrophoretic mobility shift ( 84 ) , flow cytometry ( 6 , 7 ) , immunoassay ( 4 , 26 ) , immunoprecipitation ( 6 , 7 , 26 ) , mass spectrometry ( 8 , 11 , 15 , 18 , 20 , 21 , 22 , 23 , 25 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 ) , mutation of modification site ( 4 , 6 , 24 , 84 , 85 , 86 ) , phospho-antibody ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 9 , 10 , 12 , 13 , 14 , 16 , 17 , 24 , 26 , 27 , 73 , 83 , 85 ) , western blotting ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 9 , 10 , 13 , 14 , 16 , 17 , 24 , 26 , 27 , 73 , 83 )
Disease tissue studied:	brain cancer ( 12 ) , glioblastoma ( 12 ) , glioma ( 12 ) , breast cancer ( 4 , 5 , 15 , 26 ) , HER2 positive breast cancer ( 8 ) , luminal A breast cancer ( 8 ) , luminal B breast cancer ( 8 ) , breast cancer, triple negative ( 4 , 8 , 15 ) , cervical cancer ( 84 ) , cervical adenocarcinoma ( 84 ) , chondrosarcoma ( 24 ) , colorectal cancer ( 6 , 9 , 10 , 73 ) , colorectal carcinoma ( 6 , 9 , 73 ) , gastric cancer ( 21 , 25 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 47 , 50 , 51 , 52 , 54 , 55 , 56 , 60 , 61 , 62 , 65 , 66 , 69 , 71 , 74 , 75 , 76 , 77 ) , gastric carcinoma ( 25 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 47 , 50 , 51 , 52 , 54 , 55 , 56 , 60 , 61 , 62 , 65 , 66 , 69 , 71 , 74 , 75 , 76 , 77 ) , leukemia ( 82 ) , chronic myelogenous leukemia ( 82 ) , liver cancer ( 2 ) , hepatocellular carcinoma ( 2 ) , lung cancer ( 22 , 43 , 44 , 45 , 46 , 48 , 49 , 53 , 57 , 58 , 59 , 63 , 64 , 67 , 68 , 70 , 72 , 78 ) , non-small cell lung cancer ( 22 , 43 , 44 , 45 , 46 , 48 , 49 , 53 , 57 , 58 , 59 , 63 , 64 , 67 , 68 , 70 , 72 , 78 ) , non-small cell lung adenocarcinoma ( 45 , 48 , 49 , 53 , 58 , 63 , 64 , 67 , 68 , 70 , 72 , 78 ) , non-small cell squamous cell lung carcinoma ( 45 , 48 , 49 , 53 , 58 , 78 ) , melanoma skin cancer ( 11 )
Relevant cell line - cell type - tissue:	'stem, embryonic' ( 14 ) , 'stem, induced pluripotent' ( 1 ) , 293 (epithelial) ( 6 , 7 , 17 , 24 , 26 , 83 , 84 ) , A549 (pulmonary) ( 18 ) , breast ( 4 , 8 , 15 ) , BT-549 (breast cell) ( 4 ) , colon ( 9 ) , DLD1 (intestinal) ( 9 ) , GB2 ( 12 ) , HCC366 (pulmonary) ( 22 ) , HCC78 (pulmonary) ( 22 ) , HCT116 (intestinal) ( 6 ) , HEK293T (epithelial) ( 3 , 5 , 7 , 16 , 85 ) , HeLa (cervical) ( 7 , 13 , 20 , 79 , 80 ) , HeLa S3 (cervical) ( 84 ) , HepG2 (hepatic) ( 2 ) , HOP62 (pulmonary) ( 22 ) , Hs 578T (breast cell) ( 5 ) , HT-29 (intestinal) ( 9 ) , IEC-6 (epithelial) ( 9 ) , Jurkat (T lymphocyte) ( 81 ) , K562 (erythroid) ( 20 , 82 ) , MCF-7 (breast cell) ( 26 ) , MDA-MB-231 (breast cell) ( 4 , 5 ) , MEF (fibroblast) ( 85 ) , mesangial ( 27 ) , MHCC97H (hepatic) ( 2 ) , MKN-45 (gastric) ( 21 , 23 , 25 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 47 , 50 , 51 , 52 , 54 , 55 , 56 , 60 , 61 , 62 , 65 , 66 , 69 , 71 , 74 , 75 , 76 , 77 ) , myocyte-heart ( 1 ) , NCI-H1703 (squamous) ( 23 , 45 , 48 , 49 , 53 , 58 , 78 ) , NCI-H322 (pulmonary) ( 22 ) , NCI-H3255 (pulmonary) ( 23 , 43 , 44 , 46 , 57 , 59 ) , NCI-H441 (pulmonary) ( 63 , 64 , 67 , 68 , 70 , 72 ) , RCS (chondrocyte) ( 24 ) , SW480 (intestinal) ( 6 ) , T84 (intestinal) ( 73 ) , WM239A (melanocyte) ( 11 )

Upstream Regulation
Regulatory protein:	ARMET (human) ( 1 ) , BRAF (human) ( 9 ) , C1QDC1 (human) ( 7 ) , caveolin-1 (human) ( 17 ) , CBCP1 (human) ( 16 ) , CD44 (human) ( 13 ) , CDK14 (human) ( 7 ) , CK1G1 (human) ( 3 ) , CK1G2 (human) ( 3 ) , DVL1 (human) ( 83 ) , FZD2 (human) ( 83 ) , FZD4 (human) ( 83 ) , FZD5 (human) ( 83 ) , GBA (human) ( 2 ) , GRP78 (human) ( 1 ) , KRas (human) ( 9 ) , LRP6 (human) ( 17 ) , PI4K2A (human) ( 83 ) , PIP5K1A (human) ( 83 ) , PIP5K1B (human) ( 83 ) , TMEM97 (human) ( 5 ) , WNT3 (human) ( 14 ) , WNT3A (human) ( 12 , 24 , 85 ) , WNT9B (human) ( 14 ) , WTX (human) ( 26 )
Putative in vivo kinases:	CDK14 (human) ( 7 ) , CK1D (human) ( 5 ) , CK1E (human) ( 5 ) , CK1G3 (human) ( 3 ) , ERK1 (human) ( 9 , 24 ) , GSK3B (human) ( 84 , 85 ) , QIK (human) ( 4 )
Kinases, in vitro:	CK1A (human) ( 28 ) , ERK1 (human) ( 24 ) , GSK3A (human) ( 28 ) , GSK3B (human) ( 85 ) , QIK (human) ( 4 )
Treatments:	4-HT ( 9 ) , ARN-3236 ( 4 ) , CTGF ( 27 ) , FGF2 ( 14 , 24 ) , FP1-24-2 ( 3 ) , HG-9-91-01 ( 4 ) , IFN-gamma ( 73 ) , ionomycin ( 26 ) , lithium ( 26 ) , miglustat ( 2 ) , PD184352 ( 9 ) , PDMP ( 2 ) , PI(4,5)P2 ( 83 ) , SB216763 ( 9 ) , SCH772984 ( 9 ) , siRNA ( 3 , 4 , 83 ) , SP600125 ( 9 ) , SU5402 ( 24 ) , TNF ( 73 ) , TPO ( 10 ) , tunicamycin ( 24 ) , U0126 ( 9 , 14 , 24 ) , Wnt3a ( 1 , 3 , 4 , 7 , 17 , 26 , 83 , 84 )

Downstream Regulation
Effects of modification on LRP6:	activity, induced ( 9 , 28 ) , molecular association, regulation ( 12 , 28 , 84 , 86 ) , phosphorylation ( 85 )
Effects of modification on biological processes:	carcinogenesis, induced ( 2 , 4 , 5 ) , cell cycle regulation ( 7 ) , cell growth, induced ( 4 , 5 ) , signaling pathway regulation ( 2 , 3 , 4 , 5 , 9 , 24 , 28 ) , transcription, altered ( 84 ) , transcription, induced ( 3 , 4 , 5 , 9 )
Induce interaction with:	axin 1 (human) ( 28 , 84 , 86 ) , caveolin-1 (human) ( 84 )

Disease / Diagnostics Relevance
Relevant diseases:	colorectal carcinoma ( 9 ) , liver cancer ( 2 )

References
1	Zhang Y, et al. (2022) Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Sci Transl Med 14, eabo1981 36322628 Curated Info
2	Qiu Z, et al. (2022) GBA1-dependent membrane glucosylceramide reprogramming promotes liver cancer metastasis via activation of the Wnt/β-catenin signalling pathway. Cell Death Dis 13, 508 35637196 Curated Info
3	Agajanian MJ, et al. (2022) Protein proximity networks and functional evaluation of the casein kinase 1 gamma family reveal unique roles for CK1γ3 in WNT signaling. J Biol Chem 298, 101986 35487243 Curated Info
4	Rong Z, et al. (2022) SIK2 maintains breast cancer stemness by phosphorylating LRP6 and activating Wnt/β-catenin signaling. Oncogene 35277657 Curated Info
5	Zhu H, et al. (2021) Transmembrane protein 97 exhibits oncogenic properties via enhancing LRP6-mediated Wnt signaling in breast cancer. Cell Death Dis 12, 912 34615853 Curated Info
6	Liang J, et al. (2017) miR-27a-3p targeting RXRα promotes colorectal cancer progression by activating Wnt/β-catenin pathway. Oncotarget 8, 82991-83008 29137318 Curated Info
7	Wang X, et al. (2016) Activation/Proliferation-associated Protein 2 (Caprin-2) Positively Regulates CDK14/Cyclin Y-mediated Lipoprotein Receptor-related Protein 5 and 6 (LRP5/6) Constitutive Phosphorylation. J Biol Chem 291, 26427-26434 27821587 Curated Info
8	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
9	Lemieux E, et al. (2015) Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer. Oncogene 34, 4914-27 25500543 Curated Info
10	Wu Z, et al. (2015) TPO-Induced Metabolic Reprogramming Drives Liver Metastasis of Colorectal Cancer CD110+ Tumor-Initiating Cells. Cell Stem Cell 17, 47-59 26140605 Curated Info
11	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
12	Koyama-Nasu R, et al. (2015) Thr160 of Axin1 is critical for the formation and function of the β-catenin destruction complex. Biochem Biophys Res Commun 459, 411-5 25735981 Curated Info
13	Schmitt M, et al. (2015) CD44 functions in Wnt signaling by regulating LRP6 localization and activation. Cell Death Differ 22, 677-89 25301071 Curated Info
14	Lee CT, et al. (2015) Functional consequences of 17q21.31/WNT3-WNT9B amplification in hPSCs with respect to neural differentiation. Cell Rep 10, 616-32 25640183 Curated Info
15	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
16	Li S, et al. (2014) Phosphorylation of cyclin Y by CDK14 induces its ubiquitination and degradation. FEBS Lett 588, 1989-96 24794231 Curated Info
17	Vinyoles M, et al. (2014) Multivesicular GSK3 sequestration upon Wnt signaling is controlled by p120-catenin/cadherin interaction with LRP5/6. Mol Cell 53, 444-57 24412065 Curated Info
18	Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9 23836654 Curated Info
19	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
20	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
21	Rikova K (2012) CST Curation Set: 16137; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954 Curated Info
22	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
23	Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201 22322096 Curated Info
24	Krejci P, et al. (2012) Receptor Tyrosine Kinases Activate Canonical WNT/β-Catenin Signaling via MAP Kinase/LRP6 Pathway and Direct β-Catenin Phosphorylation. PLoS One 7, e35826 22558232 Curated Info
25	Possemato A (2011) CST Curation Set: 11925; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
26	Tanneberger K, et al. (2011) Amer1/WTX couples Wnt-induced formation of PtdIns(4,5)P2 to LRP6 phosphorylation. EMBO J 30, 1433-43 21304492 Curated Info
27	Rooney B, et al. (2011) CTGF/CCN2 activates canonical Wnt signalling in mesangial cells through LRP6: implications for the pathogenesis of diabetic nephropathy. FEBS Lett 585, 531-8 21237163 Curated Info
28	Macdonald BT, Semenov MV, Huang H, He X (2011) Dissecting Molecular Differences between Wnt Coreceptors LRP5 and LRP6. PLoS One 6, e23537 21887268 Curated Info
29	Moritz A (2010) CST Curation Set: 10603; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
30	Moritz A (2010) CST Curation Set: 10611; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
31	Moritz A (2010) CST Curation Set: 10617; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
32	Moritz A (2010) CST Curation Set: 10606; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
33	Moritz A (2010) CST Curation Set: 10616; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
34	Moritz A (2010) CST Curation Set: 10602; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
35	Moritz A (2010) CST Curation Set: 10609; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
36	Moritz A (2010) CST Curation Set: 10604; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
37	Moritz A (2010) CST Curation Set: 10607; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
38	Moritz A (2010) CST Curation Set: 10610; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
39	Moritz A (2010) CST Curation Set: 10605; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
40	Moritz A (2010) CST Curation Set: 10608; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
41	Moritz A (2010) CST Curation Set: 10612; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
42	Moritz A (2010) CST Curation Set: 10601; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
43	Moritz A (2010) CST Curation Set: 10599; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
44	Moritz A (2010) CST Curation Set: 10597; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
45	Moritz A (2010) CST Curation Set: 10594; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
46	Moritz A (2010) CST Curation Set: 10598; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/Su11274; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
47	Moritz A (2010) CST Curation Set: 10600; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
48	Moritz A (2010) CST Curation Set: 10595; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Su11274; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
49	Moritz A (2010) CST Curation Set: 10596; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
50	Moritz A (2010) CST Curation Set: 10233; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
51	Moritz A (2010) CST Curation Set: 10238; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
52	Moritz A (2010) CST Curation Set: 10235; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
53	Moritz A (2010) CST Curation Set: 10240; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
54	Moritz A (2010) CST Curation Set: 10232; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
55	Moritz A (2010) CST Curation Set: 10237; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
56	Moritz A (2010) CST Curation Set: 10234; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
57	Moritz A (2010) CST Curation Set: 10241; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
58	Moritz A (2010) CST Curation Set: 10239; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
59	Moritz A (2010) CST Curation Set: 10242; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
60	Moritz A (2010) CST Curation Set: 10236; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
61	Moritz A (2010) CST Curation Set: 10231; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
62	Moritz A (2010) CST Curation Set: 10243; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
63	Moritz A (2010) CST Curation Set: 9985; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
64	Moritz A (2010) CST Curation Set: 9984; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
65	Moritz A (2010) CST Curation Set: 10021; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
66	Moritz A (2010) CST Curation Set: 10020; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
67	Moritz A (2010) CST Curation Set: 9983; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
68	Moritz A (2010) CST Curation Set: 9986; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
69	Moritz A (2010) CST Curation Set: 10022; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
70	Moritz A (2010) CST Curation Set: 9980; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
71	Moritz A (2010) CST Curation Set: 10023; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
72	Moritz A (2010) CST Curation Set: 9987; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
73	Nava P, et al. (2010) Interferon-gamma regulates intestinal epithelial homeostasis through converging beta-catenin signaling pathways. Immunity 32, 392-402 20303298 Curated Info
74	Moritz A (2010) CST Curation Set: 9374; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
75	Moritz A (2010) CST Curation Set: 9373; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
76	Moritz A (2010) CST Curation Set: 9279; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO &'\|\|' Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
77	Moritz A (2010) CST Curation Set: 9234; Year: 2010; Biosample/Treatment: cell line, MKN-45/calyculin_A & pervanadate; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
78	Moritz A (2010) CST Curation Set: 9240; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
79	Moritz A (2010) CST Curation Set: 9237; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
80	Moritz A (2010) CST Curation Set: 9243; Year: 2010; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
81	Moritz A (2010) CST Curation Set: 8838; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
82	Moritz A (2010) CST Curation Set: 8837; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
83	Pan W, et al. (2008) Wnt3a-mediated formation of phosphatidylinositol 4,5-bisphosphate regulates LRP6 phosphorylation. Science 321, 1350-3 18772438 Curated Info
84	Yamamoto H, Komekado H, Kikuchi A (2006) Caveolin is necessary for Wnt-3a-dependent internalization of LRP6 and accumulation of beta-catenin. Dev Cell 11, 213-23 16890161 Curated Info
85	Zeng X, et al. (2005) A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 438, 873-7 16341017 Curated Info
86	Tamai K, et al. (2004) A mechanism for Wnt coreceptor activation. Mol Cell 13, 149-56 14731402 Curated Info